Who Owns Aclaris Therapeutics Inc (ACRS)? 13F Institutional Holders (Q2 2026)

ACRS ranks #3670 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ACRS is a top-conviction position for BML Capital Management, LLC — at 36.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ACRS belongs to Ra Capital Management, L.p., but the position matters far more to BML Capital Management, LLC, who has 36.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its ACRS position for two straight quarters, increasing it by $32.6M to reach $53.1M today.

David Shaw has trimmed its ACRS position for two straight quarters, cutting it by $4.1M while still holding $2.2M.

ACRS is up 2.7% today, and institutions have been net buyers of $64.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ACRS reported a net loss of $75.7M over the trailing twelve months.

• Not yet profitable — net loss of $75.7M over the trailing twelve months
• Revenue declined 51.0% year over year
• Net income improved year over year, from -$134.7M to -$75.7M
• Operating cash flow was negative, using $47.1M in cash
• Current ratio of 3.36x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.56x equity — within a conventional range